000154248 001__ 154248
000154248 005__ 20240320115505.0
000154248 0247_ $$2doi$$a10.1007/s00115-020-00922-z
000154248 0247_ $$2pmid$$apmid:32409844
000154248 0247_ $$2pmc$$apmc:PMC7809002
000154248 0247_ $$2ISSN$$a0028-2804
000154248 0247_ $$2ISSN$$a1433-0407
000154248 037__ $$aDZNE-2021-00109
000154248 041__ $$aGerman
000154248 082__ $$a610
000154248 1001_ $$0P:(DE-2719)2812583$$aGörß, Doreen$$b0$$eFirst author$$udzne
000154248 245__ $$aLATE: Nicht jede Demenz ist Alzheimer – Diskussion einer neuen Krankheitsentität am Fallbeispiel : Zum aktuellen Stand der „limbic-predominant age-related TDP-43 encephalopathy“ (LATE).
000154248 260__ $$aHeidelberg$$bSpringer$$c2021
000154248 3367_ $$2DRIVER$$aarticle
000154248 3367_ $$2DataCite$$aOutput Types/Journal article
000154248 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1631283693_6054
000154248 3367_ $$2BibTeX$$aARTICLE
000154248 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000154248 3367_ $$00$$2EndNote$$aJournal Article
000154248 520__ $$aLimbic-predominant age-related TDP-43 (Transactivation response(TAR)-DNA-binding protein 43 kDa) encephalopathy (LATE) has recently been characterized as a distinct neuropathological entity within the spectrum of dementia. Neuropathological alterations in the sense of LATE were already previously described as a comorbidity to Alzheimer's disease (AD) and it has been diagnosed independently from AD pathology in autopsy studies since 2008. The framework of LATE would account for the pathogenetic impact of limbic TDP-43 proteinopathy as a driver of amnestic dementia, either together with comorbid typical AD changes or as a distinct feature. The LATE possibly explains divergent clinical observations and biomarker results in patients suffering from severe amnestic impairment without biomarker evidence of AD-related amyloid and tau alterations. Whether LATE represents a distinct neuropathological entity or is part of the spectrum of neurodegenerative diseases associated with TDP-43 is currently a matter of debate. Further studies on the role of TDP-43 in the development of amnestic dementia are urgently needed. Thus, the enrichment of an amnestic phenotype in amyloid-centered therapeutic drug studies bears the risk of higher rates of patients with TDP-43 comorbidity, which could hinder the proof of efficacy in such trials. This article presents the current state of the discussion on LATE and illustrates the concept and the clinical considerations with a case study.
000154248 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000154248 588__ $$aDataset connected to CrossRef, PubMed,
000154248 650_7 $$2Other$$aAlzheimer’s disease
000154248 650_7 $$2Other$$aDementia
000154248 650_7 $$2Other$$aProteinopathy
000154248 650_7 $$2Other$$aSNAP
000154248 650_7 $$2Other$$aTDP-43
000154248 650_7 $$2NLM Chemicals$$aDNA-Binding Proteins
000154248 650_7 $$2NLM Chemicals$$aTARDBP protein, human
000154248 650_2 $$2MeSH$$aAlzheimer Disease: diagnosis
000154248 650_2 $$2MeSH$$aAlzheimer Disease: epidemiology
000154248 650_2 $$2MeSH$$aDNA-Binding Proteins: genetics
000154248 650_2 $$2MeSH$$aHumans
000154248 650_2 $$2MeSH$$aTDP-43 Proteinopathies: genetics
000154248 7001_ $$0P:(DE-2719)2810394$$aKilimann, Ingo$$b1$$udzne
000154248 7001_ $$0P:(DE-2719)2810283$$aDyrba, Martin$$b2$$udzne
000154248 7001_ $$aNitsch, Sascha$$b3
000154248 7001_ $$aKrause, Bernd$$b4
000154248 7001_ $$0P:(DE-2719)2000026$$aTeipel, Stefan$$b5$$eLast author$$udzne
000154248 773__ $$0PERI:(DE-600)1462945-8$$a10.1007/s00115-020-00922-z$$gVol. 92, no. 1, p. 18 - 26$$n1$$p18 - 26$$tDer Nervenarzt$$v92$$x1433-0407$$y2021
000154248 8564_ $$uhttps://pub.dzne.de/record/154248/files/115_2020_Article_922.pdf$$yOpenAccess
000154248 8564_ $$uhttps://pub.dzne.de/record/154248/files/115_2020_Article_922.gif?subformat=icon$$xicon$$yOpenAccess
000154248 8564_ $$uhttps://pub.dzne.de/record/154248/files/115_2020_Article_922.jpg?subformat=icon-1440$$xicon-1440$$yOpenAccess
000154248 8564_ $$uhttps://pub.dzne.de/record/154248/files/115_2020_Article_922.jpg?subformat=icon-180$$xicon-180$$yOpenAccess
000154248 8564_ $$uhttps://pub.dzne.de/record/154248/files/115_2020_Article_922.jpg?subformat=icon-640$$xicon-640$$yOpenAccess
000154248 8564_ $$uhttps://pub.dzne.de/record/154248/files/115_2020_Article_922.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000154248 909CO $$ooai:pub.dzne.de:154248$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000154248 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812583$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000154248 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810394$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000154248 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810283$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000154248 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000026$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000154248 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000154248 9130_ $$0G:(DE-HGF)POF3-344$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lErkrankungen des Nervensystems$$vClinical and Health Care Research$$x0
000154248 9132_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000154248 9141_ $$y2021
000154248 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000154248 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-12
000154248 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-12
000154248 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-12
000154248 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-28
000154248 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-12
000154248 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNERVENARZT : 2021$$d2022-11-12
000154248 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-28
000154248 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2021-01-28$$wger
000154248 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000154248 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-12
000154248 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-12
000154248 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-12
000154248 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-28
000154248 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-12
000154248 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-12
000154248 9201_ $$0I:(DE-2719)1510100$$kAG Teipel$$lClinical Dementia Research Rostock /Greifswald$$x0
000154248 980__ $$ajournal
000154248 980__ $$aVDB
000154248 980__ $$aUNRESTRICTED
000154248 980__ $$aI:(DE-2719)1510100
000154248 9801_ $$aFullTexts